biotech / news / / MarketScreener
The biotechnology company on Thursday reported a first-quarter profit of $1.82 billion.
Amgen's adjusted earnings per share beat analyst expectations by $0.38 in the first quarter.
KEY POINTS
- Sixteen Amgen products achieved double-digit sales growth during the first quarter.
- The FDA has proposed withdrawing approval for Amgen's Tavneos due to concerns over effectiveness.
- Serious liver injuries, including eight deaths, have been linked to Amgen's Tavneos drug.
COMPANIES
Summarized by Newsio from MarketScreener. How we summarize →